CUVL — FY2026 (June year) Financial Report Analysis

Europe up, U.S. down, and a currency loss on paper

Clinuvel sells one approved drug, SCENESSE (afamelanotide), an implant that protects people with erythropoietic protoporphyria (EPP) — a rare inherited condition that makes sunlight cause severe burning pain — from light-triggered reactions. In the year to 30 June 2026 its revenue slipped 1.0% to A$94.0 million, the first annual revenue dip in the ten-year history shown in its results release. Sales through its European hub rose 13.6% while U.S. sales fell 15.0%, leaving the total roughly flat. Net profit fell 6.2% to A$33.9 million, but most of that fall came from an A$4.0 million unrealised currency loss on U.S.-dollar bank deposits rather than from the drug business itself. Excluding currency effects, pre-tax profit actually rose about 2%. All figures are in Australian dollars and come from the financial statements in the annual report the company filed with the SEC on Form 6-K.

At a glance

• U.S. revenue −15.0% to A$40.7m; European revenue +13.6% to A$52.5m. The U.S. now makes up 43% of sales, down from 50%. The company blames competitors handing EPP patients free drug and U.S. specialty centres keeping less stock on hand.
• Operating margin 43.1% (vs 43.4%). That means 43 cents of every revenue dollar was left after making the drug and paying for research, administration and marketing. Lower R&D spending offset the weaker sales.
• Cash reserves A$252.1m, up 12.5%, with no debt. That is about 2.7 times a full year of revenue. Operating cash flow of A$36.9m covered net profit 1.09 times, even after paying A$12.2m of this year's tax early.

The numbers

Where the revenue came from

Clinuvel reports a single business segment, but it breaks revenue down by where its selling entity sits. "Ireland" is the European distribution company. Revenue there rose from A$46.2m to A$52.5m. The U.S. fell from A$47.9m to A$40.7m. Rest of the world was under A$1m.

The company gives two reasons for the U.S. decline. First, "some competitors offered free drug treatment to erythropoietic protoporphyria (EPP) patients", which suggests at least some U.S. patients tried a rival therapy or a free-supply programme. Second, U.S. specialty centres moved to a "just in time" approach, ordering SCENESSE only when a patient needs a dose rather than holding stock. The second reason is a one-time timing effect: once the centres have run down their stock, orders should match patient demand again. The first is a real competitive problem that may last. Even so, management says it delivered "record SCENESSE treatment volumes to EPP patients", so the number of doses given to patients appears to have held up better than the dollar figure.

Gross margin, the share of revenue left after the cost of making and delivering the drug, slipped from 84.4% to 83.2% because the cost of revenues rose 6.8% while sales fell.

Costs: R&D down, administration up

Total expenses were almost unchanged at A$53.5m (−0.5%), but their mix shifted:

• R&D fell 12.6% to A$18.1m. The results presentation puts this down to the "cyclical timing of CUV105 clinical program completion". CUV105 is the Phase III vitiligo trial; patient enrolment is complete and results are pending. That makes the lower spend a pause rather than a cut: costs are likely to rise again when the next study starts.
• General and administrative costs rose 19.5% to A$11.2m. The presentation attributes this to one-off Nasdaq listing costs. The ADSs moved to a Level II Nasdaq listing on 20 July 2026. Audit fees alone more than doubled, from A$0.24m to A$0.54m, reflecting the extra work of meeting SEC reporting rules.
• Communications and marketing fell 5.3% to A$8.4m, which the presentation describes as discretionary cuts.

What the headline numbers hide

• The profit decline comes mostly from currency, not the business. Clinuvel held A$72.5m of U.S.-dollar term deposits at year-end, up from A$30.0m. When the Australian dollar strengthens, those deposits are worth fewer Australian dollars, and that loss goes through the income statement even though nothing was sold. The swing from a A$0.9m gain to a A$4.0m loss cost A$4.9m before tax. With both years' currency effects removed, pre-tax profit rose from A$50.6m to A$51.6m (+1.9%). The financial-risk note says a 9.1% rise in the Australian dollar against the U.S. dollar (and 7.9% against the euro) would cut profit by another A$5.9m, so this risk has grown as the company has moved more of its cash into U.S. dollars.
• About a fifth of pre-tax profit comes from interest. Interest income rose to A$10.4m on the larger cash pile. That money is real, but it depends on interest rates and cash balances rather than on drug sales. Income from operations, which excludes interest, fell 1.8%.
• Cash conversion is good. Operating cash flow of A$36.9m was 1.09 times net profit (1.14 times last year). Customer receipts of A$99.0m exceeded reported revenue. Tax payments jumped to A$23.4m from A$15.7m because the company chose to prepay A$12.2m of FY2026 tax. Without that prepayment, management says cash reserves would have reached about A$264m. After A$1.6m of equipment spending and A$0.2m of lease payments, free cash flow was about A$35.1m.
• Working capital is shrinking, not swelling. Trade and other receivables fell 14.6% to A$23.5m and inventory fell 22.0% to A$6.9m, both faster than the 1% drop in revenue. When sales slip, rising receivables or unsold stock can be a warning sign. Neither appears here.
• EPS fell slightly more than profit. Diluted EPS fell 7.0% against a 6.2% fall in net profit. The number of shares used to calculate diluted EPS rose 0.7% as performance rights granted to staff increased. There was no buyback this year. Share-based pay, a non-cash cost, rose to A$2.3m from A$1.4m.
• The tax rate fell slightly, from 29.8% to 28.8%, which helped net profit by about A$0.5m. That is too small to change the picture.
• A presentation inconsistency: the income statement shows the A$1.67m foreign-currency translation item in other comprehensive income as a gain. The statement of changes in equity and the cash-flow statement both treat it as a loss, and the equity balances only reconcile on that basis. This does not affect net profit.
• No guidance to compare against. Clinuvel does not give revenue or profit forecasts. Its outlook is expressed as pipeline and expansion milestones (below).

The bigger strategic moves

The results came with an announcement that the board is considering a scheme of arrangement, a court-approved restructuring, under which a new foreign holding company would list its ordinary shares on Nasdaq and Clinuvel would delist from the ASX. Operating headquarters will move to the U.S. from 1 January 2027. No final decision has been made. The deal would need approval from shareholders, the court and regulators. The board declared a fully franked dividend of A$0.05 per share, the same as last year, totalling about A$2.5m, or 7% of net profit.

Takeaway: Clinuvel's FY2026 dip is mostly an accounting effect of holding more U.S.-dollar cash while the Australian dollar strengthened. The underlying business earned slightly more before tax than a year ago. The real concern is the 15% fall in U.S. sales, the company's most important market for its planned expansion: management partly blames competitors giving EPP patients free drug, and that problem may not fix itself.

What to watch

The biggest event in the next six months is the topline readout of the CUV105 Phase III vitiligo trial, which the company says is due in the second half of calendar 2026. Vitiligo is a common condition that causes patches of skin to lose pigment, so positive results would create a much larger market than EPP. Negative results would leave Clinuvel dependent on a one-drug rare-disease business where U.S. sales are already falling. Other dated milestones are a first European filing for NEURACTHEL (H2 2026), an adolescent-EPP filing for SCENESSE (H2 2027), and growing the number of U.S. and Canadian treatment centres from 134 to a targeted 190 by 2027. For the next report, the half-year to 31 December 2026, watch two things: whether U.S. revenue stabilises once specialty centres have finished running down their stock, and whether R&D rises again as the vitiligo programme moves forward. With A$252m in cash and no debt, the company can pay for all of this itself. The open question is whether that cash produces a second approved use for the drug before U.S. revenue falls further.